SpringWorks Therapeutics, Inc. - common stock (NQ:SWTX)

46.99 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about SpringWorks Therapeutics, Inc. - common stock

< Previous 1 2 3 4 5 6 Next >

Get In Now. 7 Stocks That Are Set to Soar. ↗

April 13, 2023

While it’s always difficult to determine which stocks to buy might break out imminently, speculators should watch these ideas.

Via InvestorPlace

SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors

March 08, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

March 01, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights

February 28, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

4 Analysts Have This to Say About SpringWorks Therapeutics ↗

December 01, 2022

Via Benzinga

Analyst Ratings for SpringWorks Therapeutics ↗

November 04, 2022

Within the last quarter, SpringWorks Therapeutics (NASDAQ:SWTX) has observed the following analyst ratings:

Via Benzinga

SpringWorks Shares Pop After Expanded Multiple Myeloma Pact With GSK ↗

September 07, 2022

Via Benzinga

SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors

February 27, 2023

– PDUFA Action Date Set for August 27, 2023 –

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference

January 09, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

Analyst Ratings for SpringWorks Therapeutics ↗

August 09, 2022

Within the last quarter, SpringWorks Therapeutics (NASDAQ:SWTX) has observed the following analyst ratings:

Via Benzinga

HC Wainwright Believes Ayala's Initial Cancer Data Is Encouraging ↗

July 06, 2022

Via Benzinga

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors

December 27, 2022

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022 ↗

December 01, 2022

Via Benzinga

How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market ↗

November 23, 2022

Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years.

Via Benzinga

SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference

November 22, 2022

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

SpringWorks Therapeutics: Q3 Earnings Insights ↗

November 03, 2022

SpringWorks Therapeutics (NASDAQ:SWTX) reported its Q3 earnings results on Thursday, November 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

November 03, 2022

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028

October 12, 2022

Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide...

Via FinancialNewsMedia

SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors

September 29, 2022

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday ↗

September 13, 2022

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.

Via Benzinga

NIO, Lucid Group And Other Big Gainers From Monday ↗

September 13, 2022

U.S. stocks closed higher with the Dow Jones surging more than 200 points on Monday. Here is the list of some big stocks moving higher in the previous session.

Via Benzinga

Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday ↗

August 11, 2022

Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 10, 2022

Via Benzinga

Why Plug Power Is Trading Higher By Around 14%, Here Are 73 Stocks Moving In Wednesday's Mid-Day Session ↗

August 10, 2022

Gainers BioAtla, Inc. (NASDAQ: BCAB) gained 50.1% to $5.42 following Q2 results. Euro Tech Holdings Company Limited (NASDAQ: CLWT) surged 39.5% to $2.0380.

Via Benzinga

SpringWorks Therapeutics: Q2 Earnings Insights ↗

August 04, 2022

SpringWorks Therapeutics (NASDAQ:SWTX) reported its Q2 earnings results on Thursday, August 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch ↗

July 20, 2022

One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a...

Via Benzinga

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in SpringWorks Therapeutics, Inc. with Losses to Contact the Firm

June 16, 2022

From The Schall Law Firm

Via Business Wire

SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch ↗

June 13, 2022

HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week.

Via Benzinga

70 Biggest Movers From Friday ↗

May 31, 2022

Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.